A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Early breast cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 24 Sep 2015 Planned primary completion date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov record.
- 24 Sep 2015 Planned primary completion date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov record.
- 24 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.